| abstract |
Insulin dependent diabetes mellitus is treated by administering to a patient during preclinical or early onset stages of the disease a therapeutically effective dose of an alpha interferon antagonist. Suitable antagonist include anti-alpha interferon neutralizing antibodies, neutralizing antibodies directed against the alpha interferon receptor polypeptides, soluble preparations of the alpha interferon receptor, alpha interferon fragments and the like. |